Nebenwirkungen · Poherdy
Poherdy 420 mg concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 8–9
HOS-153628 · Präparat HOS-101026
8 The safety of pertuzumab has been evaluated in more than 6,000 patients in Phase I, II, and III trials in patients with various malignancies and predominantly treated with pertuzumab in combination with other antineoplastic agents. Those studies included the pivotal trials CLEOPATRA (n=808), NEOSPHERE (n=417), TRYPHAENA (n=225), and APHINITY (n=4804) [pooled in Table 2]. The safety of pertuzumab was generally consistent across studies, although the incidence and most common adverse drug reactions (ADRs) varied depending on whether pertuzumab was administered as monotherapy or with concomitant anti-neoplastic agents.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-14T12:22:00Z · SHA-256 e51bba73aa849edde25c8bb5504db0140aa175ccec2e74e1ff7ef3ea305b337a · Passage b8449551e92c8a40d9622279af0b4d39a53c53fe1511b9a44ad2c87374be4e65 · Zeichen 83–709 im Abschnitt